2002 JAN 10 - (NewsRx.com & NewsRx.net) -- Thousands of patients affected by acute myeloid leukemia (AML) may benefit from new National Comprehensive Cancer Network (NCCN) guidelines regarding the appropriate treatment of AML, including the use of Mylotarg (gemtuzumab ozogamicin for injection) in specific clinical situations, according to Wyeth-Ayerst Laboratories.
Mylotarg is indicated for the treatment of patients with CD33[superscript]+ AML in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performance status and organ dysfunction has not …
No comments:
Post a Comment